Barinthus Biotherapeutics (BRNS) Receivables - Other (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Receivables - Other came in at $1.2 million in Q1 2026, down 58.89% YoY from $3.0 million in Q1 2025, and up 11.19% on a QoQ basis from $1.1 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Receivables - Other (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Receivables - Other data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Receivables - Other fell 58.89% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 58.89% YoY) and the FY2025 annual result came in at $1.1 million, down 84.48% from the prior year.
- Receivables - Other advanced to $1.2 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $17.0 million in Q2 2022 to a low of $1.1 million in Q4 2025.
- A 5-year average of $5.5 million and a median of $4.5 million in 2022 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2022 — Receivables - Other jumped 274.02% — and 2025, when it tumbled 84.48%.
- Tracing BRNS's Receivables - Other over 5 years: stood at $4.5 million in 2022, then rose by 8.08% to $4.9 million in 2023, then jumped by 45.46% to $7.1 million in 2024, then plunged by 84.48% to $1.1 million in 2025, then climbed by 11.19% to $1.2 million in 2026.
- The last three Receivables - Other figures came in at $1.2 million (Q1 2026), $1.1 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Mn |
| Jun 30, 2026 | 1.28 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 7.14 Mn |
| Dec 31, 2024 | 7.14 Mn |
| Sep 30, 2024 | 14.97 Mn |
| Sep 30, 2024 | 14.97 Mn |
| Jun 30, 2024 | 4.52 Mn |
| Jun 30, 2024 | 4.52 Mn |
| Mar 31, 2024 | 5.20 Mn |
| Mar 31, 2024 | 5.20 Mn |